08:28 AM EDT, 10/13/2025 (MT Newswires) -- ADC Therapeutics ( ADCT ) said Monday it has agreed to sell its equity securities to certain institutional investors through a $60 million private investment in public equity financing.

The company is selling 11.3 million common shares at $4 per share and pre-funded warrants to buy 3.8 million shares at $3.90 per pre-funded warrant, it said.

Net proceeds will be allocated toward the commercial expansion of CD19-directed antibody drug conjugate Zynlonta and to finance working capital and general corporate purposes, said ADC Therapeutics ( ADCT ), which expects deal completion on Oct. 27.

The company's shares were up over 8% in recent Monday premarket activity.